{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:51:52Z","timestamp":1773294712856,"version":"3.50.1"},"reference-count":48,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,9,1]]},"abstract":"<jats:p>Objective. The objective of this study was to investigate the long-term safety and efficacy of risperidone in disruptive behavior disorders in children with subaverage IQs. Disruptive behavior disorders were defined as oppositional defiant disorder, disruptive behavior disorder, and conduct disorder as per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.<\/jats:p><jats:p>Methods. This was a 48-week open-label (OL) extension study of risperidone in 77 children diagnosed with a disruptive behavior disorder, and either borderline intellectual function or mild or moderate mental retardation who had participated in a previous 6-week, double-blind (DB) study and completed at least 2 weeks of DB therapy. Children, aged 5 to 12 years inclusive, who had: 1) a DSM-IV Axis I diagnosis of conduct disorder, oppositional defiant disorder, or disruptive behavior disorder- not otherwise specified; 2) a parent-assessed rating of \u226524 in the Conduct Problem Subscale of the Nisonger-Child Behavior Rating Form28; 3) a DSM-IV Axis II diagnosis of mild or moderate mental retardation or borderline intellectual functioning with an IQ \u226536 and \u226484; and 4) a score of \u226484 on the Vineland Adaptive Behavior Scale. Participants received oral solution risperidone given at a once daily dose of between 0.02 and 0.06 mg\/kg for a maximum of 48 weeks. Participants in the DB study who had been randomized would have had a maximum of 54 weeks of risperidone therapy. Study visits were scheduled at entry, weekly for the first month, and monthly for the remaining 11 months.<\/jats:p><jats:p>Results. Baseline scores on the conduct problem subscale at the start of the previous DB study were similar for both treatment groups: mean values of 33.5 and 33.3 were recorded for placebo- and risperidone-treated participants, respectively. At the time of the OL baseline visit, mean Conduct Problem Subscale scores were lower in those who had been treated with risperidone than in those who remained risperidone-nai\u0308ve (17.5 and 26.1, respectively). Within 1 week of receiving daily risperidone therapy (mean daily dose: 1.38 mg), those participants who had been risperidone-nai\u0308ve at OL entry showed a rapid improvement in the Conduct Problem Subscale score. At the week 1 assessment, the mean change from baseline for those who had been risperidone-nai\u0308ve at OL entry was similar in magnitude to the change from DB baseline recorded for participants who had received risperidone in the DB study. This mean improvement was sustained in both groups throughout the remainder of the OL study.<\/jats:p><jats:p>At study endpoint, those participants who had been risperidone-nai\u0308ve at OL entry experienced a highly significant mean decrease from OL baseline in the mean Conduct Problem Subscale score of 10.6 \u00b1 2.18. The response to risperidone in the OL trial remained stable in those participants who had been treated with risperidone in the previous DB trial; in this group, the mean change at study endpoint from OL baseline was a nonsignificant decrease of 1.26 \u00b1 1.45. At DB baseline, 68% of participants had a Clinical Global Impression assessment rated as marked, severe, or extremely severe. By DB study endpoint, only 17% of participants (15% of whom had received placebo and 19% of whom had been treated with risperidone in the previous study) had this severe an assessment; 63% of participants had symptoms rated as either none, very mild, or mild. Similarly, highly significant decreases from baseline in the Vineland Adaptive Behavior Scale rating of the most troublesome symptom (often identified as either aggression (hitting, fighting, or temper tantrums) were observed by study endpoint after 48 weeks of risperidone therapy. For those participants who had received placebo in the previous study, a mean decrease of 47.1 \u00b1 4.87 mm from a DB baseline of 79.4 \u00b1 2.69 mm was observed. In those who had received risperidone, a mean decrease of 43.5 \u00b1 4.57 mm from a DB baseline of 79.3 \u00b1 3.66 mm was observed. Five subgroup analyses of the primary efficacy outcome were performed. These included analysis by diagnosis (conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified), degree of mental retardation (borderline, mild, moderate), and presence or absence of somnolence, attention-deficit\/hyperactivity disorder, and psychostimulants.<\/jats:p><jats:p>The results showed that the efficacy of risperidone was not affected by type of disorder, level of retardation, presence\/absence of somnolence or attention-deficit\/hyperactivity disorder, or use of psychostimulants. Adverse events were reported for 76 participants; none were serious and most were mild\/moderate in severity. Somnolence (52%), headache (38%), and weight gain (36%) were the most common adverse events. The degree of sedation was mild and not associated with cognitive deterioration. In fact, for most parameters assessed on the modified California Verbal Learning Test (a test for verbal learning and memory), there were statistically significant improvements relative to both OL and DB baselines in the mean scores. In addition, statistically significant improvements over baseline were also seen for some Continous Performance Task (which is a test for attention and impulsivity) parameters. Overall, no deterioration of cognitive function was observed while participants were treated with risperidone.<\/jats:p><jats:p>Almost half of the 8.5 kg gained was attributable to normal growth. Asymptomatic peak prolactin levels were observed within 4 weeks of beginning risperidone treatment and declined over time to within normal range. At study endpoint, mean prolactin levels were statistically significantly greater than baseline only in male participants but still &amp;lt;20 ng\/mL, which is within the normal range. Twenty participants experienced mild or moderate extrapyramidal symptoms, although none withdrew for this reason.<\/jats:p><jats:p>Conclusions. Risperidone, administered as an oral solution at a mean dose of 1.38 mg\/d (range: 0.02\u20130.06 mg\/kg\/d) for 1 year, was well tolerated, safe, and showed maintenance of effect in the treatment of disruptive behavior disorders in children aged 5 to 12 years with subaverage IQs.<\/jats:p>","DOI":"10.1542\/peds.110.3.e34","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e34-e34","source":"Crossref","is-referenced-by-count":158,"title":["Long-Term Safety and Efficacy of Risperidone for the Treatment of Disruptive Behavior Disorders in Children With Subaverage IQs"],"prefix":"10.1542","volume":"110","author":[{"given":"Atilla","family":"Turgay","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Clinical Affairs, Janssen-Ortho Inc, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Royal University Hospital, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Fisman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, London Health Sciences Centre, London, Ontario, Canada and the Conduct Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,9,1]]},"reference":[{"key":"2021121006234354400_R1","doi-asserted-by":"crossref","unstructured":"Steiner H. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry.1997;36(suppl):122S\u2013139S","DOI":"10.1097\/00004583-199710001-00008"},{"key":"2021121006234354400_R2","doi-asserted-by":"crossref","unstructured":"Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. Child Adolesc Psychiatry Clin North Am.1994;3:177\u2013194","DOI":"10.1016\/S1056-4993(18)30495-4"},{"key":"2021121006234354400_R3","doi-asserted-by":"crossref","unstructured":"Dosen A. Diagnosis and treatment of psychiatric and behavioral disorders in mentally retarded individuals: the state of the art. J Intellect Disabil Res.1993;37(suppl):1\u20137","DOI":"10.1111\/j.1365-2788.1993.tb00887.x"},{"key":"2021121006234354400_R4","doi-asserted-by":"crossref","unstructured":"Gillberg C, Persson E, Grufman N, Themner U. Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. Br J Psychiatry.1986;149:68\u201374","DOI":"10.1192\/bjp.149.1.68"},{"key":"2021121006234354400_R5","doi-asserted-by":"crossref","unstructured":"Campbell SB, Ewing LJ. Follow-up of hard-to-manage preschoolers: adjustment at age 9 and predictors of continuing symptoms. J Child Psychol Psychiatry.1990;31:871\u2013889","DOI":"10.1111\/j.1469-7610.1990.tb00831.x"},{"key":"2021121006234354400_R6","doi-asserted-by":"crossref","unstructured":"Moffitt TE. Juvenile delinquency and attention deficit disorder: boy\u2019s developmental trajectories from age 3 to age 15. Child Dev.1990;61:893\u2013910","DOI":"10.1111\/j.1467-8624.1990.tb02830.x"},{"key":"2021121006234354400_R7","doi-asserted-by":"crossref","unstructured":"Kazdin AE. Conduct Disorder in Childhood and Adolescence. 2nd ed. Thousand Oaks, CA: Sage Publications; 1995","DOI":"10.4135\/9781483345406"},{"key":"2021121006234354400_R8","doi-asserted-by":"crossref","unstructured":"Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry.1999;40:57\u201387","DOI":"10.1111\/1469-7610.00424"},{"key":"2021121006234354400_R9","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994"},{"key":"2021121006234354400_R10","doi-asserted-by":"crossref","unstructured":"Bardone AM, Moffitt TE, Caspi A, Dickson N, Stanton WR, Silva PA. Adult physical health outcomes of adolescent girls with conduct disorder, depression, and anxiety. J Am Acad Child Adolesc Psychiatry.1998;37:594\u2013601","DOI":"10.1097\/00004583-199806000-00009"},{"key":"2021121006234354400_R11","doi-asserted-by":"crossref","unstructured":"Satterfield JH, Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry.1997;36:1726\u20131735","DOI":"10.1097\/00004583-199712000-00021"},{"key":"2021121006234354400_R12","doi-asserted-by":"crossref","unstructured":"Robins LN. Sturdy childhood predictors of adult antisocial behaviour: replications from longitudinal studies. Psychol Med.1978;8:611\u2013622","DOI":"10.1017\/S0033291700018821"},{"key":"2021121006234354400_R13","doi-asserted-by":"crossref","unstructured":"Robins LN. Conduct disorder. J Child Psychol Psychiatry.1991;32:193\u2013212","DOI":"10.1111\/j.1469-7610.1991.tb00008.x"},{"key":"2021121006234354400_R14","doi-asserted-by":"crossref","unstructured":"Kaplan SL, Simms RM, Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry.1994;33:35\u201344","DOI":"10.1097\/00004583-199401000-00006"},{"key":"2021121006234354400_R15","doi-asserted-by":"crossref","unstructured":"Aman MG, Singh NN. Patterns of drug use, methodological considerations, measurement techniques, and future trends. In: Aman MG, Singh NN, eds. Psychopharmacology of the Developmental Disabilities. New York, NY: Springer Verlag; 1988:1\u201328","DOI":"10.1007\/978-1-4613-8774-9_1"},{"key":"2021121006234354400_R16","doi-asserted-by":"crossref","unstructured":"Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry.1984;41:650\u2013656","DOI":"10.1001\/archpsyc.1984.01790180020002"},{"key":"2021121006234354400_R17","doi-asserted-by":"crossref","unstructured":"Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry.1995;34:445\u2013453","DOI":"10.1097\/00004583-199504000-00011"},{"key":"2021121006234354400_R18","doi-asserted-by":"crossref","unstructured":"Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry.2000;57:649\u2013654","DOI":"10.1001\/archpsyc.57.7.649"},{"key":"2021121006234354400_R19","unstructured":"Klein RG. Preliminary results: lithium effects in conduct disorders. Proceedings 144th Annual Meeting of the APA;1991:119\u2013120"},{"key":"2021121006234354400_R20","doi-asserted-by":"crossref","unstructured":"Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. Am J Psychiatry.1997;154:554\u2013555","DOI":"10.1176\/ajp.154.4.554"},{"key":"2021121006234354400_R21","doi-asserted-by":"crossref","unstructured":"Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry1997;54:1073\u20131080","DOI":"10.1001\/archpsyc.1997.01830240023003"},{"key":"2021121006234354400_R22","doi-asserted-by":"crossref","unstructured":"Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry.1991;30:246\u2013256","DOI":"10.1097\/00004583-199103000-00013"},{"key":"2021121006234354400_R23","doi-asserted-by":"crossref","unstructured":"Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. Mental Retardation Dev Disabil Res Rev.1999;5:253\u2013263","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R"},{"key":"2021121006234354400_R24","doi-asserted-by":"crossref","unstructured":"Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry.2000;39:509\u2013516","DOI":"10.1097\/00004583-200004000-00021"},{"key":"2021121006234354400_R25","doi-asserted-by":"crossref","unstructured":"Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Pyschopharmacol.2001;11:5\u201313","DOI":"10.1089\/104454601750143348"},{"key":"2021121006234354400_R26","unstructured":"Snyder R, Turgay A, Aman MG, Binder C, Fisman S, Carroll A, and the Risperidone Conduct Study Group. Effects of risperidone in conduct and disruptive behavior disorder in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. In press"},{"key":"2021121006234354400_R27","unstructured":"Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the Risperidone Disruptive Behavior Study Group. Risperidone treatment of children with disruptive behavior symptoms and subaverage IQs: a double-blind, placebo-controlled study. Am J Psychiatry. In press"},{"key":"2021121006234354400_R28","doi-asserted-by":"crossref","unstructured":"Aman MG, Tasse\u0301 MJ, Rojahn J, Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil.1996;17:41\u201357","DOI":"10.1016\/0891-4222(95)00039-9"},{"key":"2021121006234354400_R29","unstructured":"Findling RL, Aman MG, De Smedt G, Derivan MD, the Risperidone Disruptive Behavior Study Group. A long-term open-label study of risperidone in children with severe disruptive behaviors and subaverage IQs. Am J Psychiatry. In press"},{"key":"2021121006234354400_R30","unstructured":"Sparrow SS, Balla DA, Cicchetti CV. Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service Inc; 1984"},{"key":"2021121006234354400_R31","unstructured":"Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci.1980;7:233"},{"key":"2021121006234354400_R32","unstructured":"Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test, Children\u2019s Version, Manual. Orlando, FL: Psychological Corp\/Harcourt, Brace & Co; 1998"},{"key":"2021121006234354400_R33","doi-asserted-by":"crossref","unstructured":"Tasse\u0301 MJ, Aman MG, Hammer D, Rojahn J. The Nisonger Child Behavior Rating Form: age and gender effects and norms. Res Dev Disabil.1996;17:59\u201375","DOI":"10.1016\/0891-4222(95)00037-2"},{"key":"2021121006234354400_R34","doi-asserted-by":"crossref","unstructured":"Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry.1997;36:1715\u20131725","DOI":"10.1097\/00004583-199712000-00020"},{"key":"2021121006234354400_R35","doi-asserted-by":"crossref","unstructured":"Lalonde J, Turgay A, Hudson JI. Attention-deficit hyperactivity disorder subtypes and comorbid disruptive behavior disorders in a child and adolescent mental health clinic. Can J Psychiatry.1998;43:623\u2013628","DOI":"10.1177\/070674379804300612"},{"key":"2021121006234354400_R36","doi-asserted-by":"crossref","unstructured":"Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr.1979;32:607\u2013629","DOI":"10.1093\/ajcn\/32.3.607"},{"key":"2021121006234354400_R37","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry.1999;156:1686\u20131696","DOI":"10.1176\/ajp.156.11.1686"},{"key":"2021121006234354400_R38","doi-asserted-by":"crossref","unstructured":"Taylor DM, McAskill R. Atypical antipsychotics and weight gain\u2014a systematic review. Acta Psychiatr Scand.2000;101:416\u2013432","DOI":"10.1034\/j.1600-0447.2000.101006416.x"},{"key":"2021121006234354400_R39","unstructured":"Hechtman L. Attention deficit hyperactivity disorder. In: Hechtman L, ed. Do They Grow Out of it? Long-Term Outcome of Childhood Disorders. Washington, DC: American Psychiatric Press; 1996:17\u201338"},{"key":"2021121006234354400_R40","unstructured":"Robins LN. Deviant Children Grown Up. Baltimore, MD: Williams and Wilkins; 1966"},{"key":"2021121006234354400_R41","unstructured":"Weis G, Hechtman L. Hyperactive Children Grown Up. New York, NY: Guilford Press; 1993"},{"key":"2021121006234354400_R42","doi-asserted-by":"crossref","unstructured":"Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol.2000;10:19\u201326","DOI":"10.1089\/cap.2000.10.19"},{"key":"2021121006234354400_R43","doi-asserted-by":"crossref","unstructured":"Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatry Clin North Am1992;15:69\u201385","DOI":"10.1016\/S0193-953X(18)30258-2"},{"key":"2021121006234354400_R44","doi-asserted-by":"crossref","unstructured":"Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry.1999;38:537\u2013545","DOI":"10.1097\/00004583-199905000-00015"},{"key":"2021121006234354400_R45","doi-asserted-by":"crossref","unstructured":"Kazdin AE. Treatment of antisocial behavior in children: current status and future directions. Psychol Bull.1987;102:187\u2013203","DOI":"10.1037\/0033-2909.102.2.187"},{"key":"2021121006234354400_R46","doi-asserted-by":"crossref","unstructured":"Kazdin A, Wassell G. Therapeutic changes in children, parents, and families resulting from treatment of children with conduct problems. J Am Acad Child Adolesc Psychiatry.2000;39:414\u2013420","DOI":"10.1097\/00004583-200004000-00009"},{"key":"2021121006234354400_R47","doi-asserted-by":"crossref","unstructured":"Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry.1993;32:577\u2013581","DOI":"10.1097\/00004583-199305000-00013"},{"key":"2021121006234354400_R48","doi-asserted-by":"crossref","unstructured":"Kewley G. Risperidone in comorbid ADHD and ODD\/CD. J Am Acad Child Adolesc Psychiatry.1999;38:1327\u20131328","DOI":"10.1097\/00004583-199911000-00002"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/3\/e34\/1116122\/pe0902000e34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/3\/e34\/1116122\/pe0902000e34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:34:16Z","timestamp":1682746456000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/110\/3\/e34\/64159\/Long-Term-Safety-and-Efficacy-of-Risperidone-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,1]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,9,1]]},"published-print":{"date-parts":[[2002,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.110.3.e34","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,1]]}}}